Tag: Cancer: Cervical
FIGO 2018 Staging Ups Discrimination of Stage 1B Cervical Cancer
Classifying all women with positive lymph nodes into single stage yields highly variable survival rates
Higher Surgical Volume May Improve Outcomes in Cervical Cancer
Findings show radical hysterectomy at high-volume centers tied to better survival in early cervical cancer
Some Cervical Cancer Screening Strategies More Cost-Effective
Most lifetime QALYs seen with cytologic testing every three years, repeated for ASC-US
Cervical Adenocarcinoma Rates Increased in Some Populations
Increasing and stabilizing incidence trends seen for several subpopulations; declines attenuated in SCC
CDC: Recent Decline Seen in High-Grade Cervical Lesions
Vast majority of cervical precancer cases attributable to HPV types targeted by 9-valent HPV vaccine
Histologic Clearance of CIN2/3 Seen With HPV Therapeutic Vaccine
In phase II trial, rate of complete resolution of CIN2/3 significantly higher for vaccine versus placebo group
Drop Seen in Preinvasive Cervical Disease With HPV Vaccination
Vaccine effectiveness increased for immunization at younger age
Brachytherapy Boost Ups Survival in Locally Advanced Cervical Cancer
Findings observed regardless of treatment duration; disparities for brachytherapy use seen in vulnerable populations
Decline Observed in HPV Type 16/18 Cervical Precancers in U.S.
Greatest declines seen among vaccinated women; decreases also seen in unvaccinated women
44.4 Million Estimated to Be Diagnosed With Cervical Cancer by 2069
From 2020 to 2069, 6.7 to 7.7 million cases could be averted by scaling up HPV vaccination by 2020
